NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

What are “indirect costs” for universities? Why are some young scientists looking at opportunities abroad? And why are AI drug developers so secretive?

We bring on biotech reporter Jonathan Wosen to discuss the NIH’s decision to dramatically cut funding for overhead costs paid to research institutions and the potential implications for U.S. biomedical innovation.

Read the rest…